Allergan

Allergan, Medytox enter licensing agreement

Friday, September 27, 2013 10:49 AM

Allergan, a multi-specialty healthcare company, and Medytox, a research-based biopharmaceutical company, have entered into a license agreement. Allergan will pay Medytox an upfront payment of $65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize neurotoxin product candidates currently in development, including a potential liquid-injectable product.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »

Allergan to acquire MAP Pharmaceuticals

Wednesday, January 23, 2013 12:18 PM

Allergan and MAP Pharmaceuticals, both based in California, have jointly announced a definitive merger agreement whereby Allergan will acquire 100% of MAP Pharmaceuticals shares for $25 per share. MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies in neurology, including Levadex, an orally inhaled drug for the potential acute treatment of migraine in adults which is currently is under review with the FDA.

More... »

Omeros appoints Mitro as vice president, sales and marketing

Tuesday, December 4, 2012 08:00 AM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company focused on products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas A. Mitro as vice president of sales and marketing.

More... »

Allergan to acquire SkinMedica for $350M

Monday, November 19, 2012 09:22 AM

Allergan, a multi-specialty health care company, has entered into a definitive agreement to acquire SkinMedica, a privately held,  topical aesthetics skin care business.

More... »

Aclaris raises $21M in Series A Financing

Thursday, October 25, 2012 07:30 AM

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

More... »

Allergan opens NJ facility

Tuesday, September 4, 2012 12:39 PM

Irvine, Calif.-based Allergan has opened its first large facility in New Jersey, the R&D Center in Bridgewater, N.J.

More... »

Allergan, Molecular Partners form two exclusive alliances in eye disease

Tuesday, August 21, 2012 10:24 AM

Allergan, a multi-specialty health care company based in Medford, Mass., and Molecular Partners, a privately-owned Swiss biotech focused on a class of biological drugs known as DARPins, have significantly expanded their existing relationship by entering into two separate agreements to discover, develop and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

More... »

Allergan and Molecular Partners enter into license agreement

Wednesday, May 4, 2011 12:29 PM

Allergan and Molecular Partners have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin(r) protein targeting VEGF under investigation for the treatment of retinal diseases.

More... »

Astellas Pharma Europe appoints Ken Jones as president and CEO

Monday, April 11, 2011 12:34 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Ken Jones as its president and CEO.  Jones was formerly COO at Astellas Pharma Europe.

More... »